Market Cap 57.75M
Revenue (ttm) 0.00
Net Income (ttm) -75.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.38
Volume 1,206,000
Avg Vol 4,602,628
Day's Range N/A - N/A
Shares Out 44.42M
Stochastic %K 44%
Beta 0.56
Analysts Sell
Price Target $7.00

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 619 3990
Address:
111 S. Wood Avenue, Unit #100, Iselin, United States
SteelerJon
SteelerJon Oct. 25 at 11:45 PM
$OTLK Folks do yourself a favor block this guy. If not, quit reposting his posts so those of us who have blocked him don’t have to see your discussions….appreciate it…Thanks 😎🏦🏦
1 · Reply
RJtrade22
RJtrade22 Oct. 25 at 9:54 PM
$OTLK ok when’s the run up
1 · Reply
IniG
IniG Oct. 25 at 9:48 PM
$OTLK Thats no new information: the number of patients are growing and market is getting bigger. I think you believe in monopoly and not in competition. Lytenava has a very good advantage over all these that its a cost effective option and still works well.
0 · Reply
IniG
IniG Oct. 25 at 9:43 PM
$OTLK I don't know much about this therapy but I read this in your shared link. - Adverum had previously assessed the intravitreal injection in diabetic macular edema, an effort that was eventually discontinued after a patient ***went blind in the treated eye***. - The CVR entitles the holder to receive up to a total of $8.91 cash if ixo-vec is approved within ***seven years***
0 · Reply
updownsides
updownsides Oct. 25 at 9:25 PM
$OTLK You don't even know what your invested in. They have zero pipeline. Here is upcoming competition in a crowded space. Late/early-stage wet AMD drugs: ABBV-RGX-314 (Regenxbio/AbbVie, Ph3), ADVM-022 Ixo-vec (Adverum, Ph3), Tarcocimab KSI-301 (Kodiak, Ph3), 4D-150 (4DMT, Ph3), GB-102 (Graybug, Ph2b), OPT-302 (Opthea, Ph3 combo VEGF-C/D), EYP-1901 (EyePoint, Ph2), RGX-314 suprachoroidal (Regenxbio, Ph2), Faricimab Vabysmo (Roche, approved), Susvimo PDS (Roche, approved/relaunch). Some can eliminate injections altogether.
1 · Reply
NeurNet
NeurNet Oct. 25 at 7:14 PM
$OTLK @GenerallyGentle Your answer is very... relevant! Even if their (ticker ADVM : "ixo-vec") new gene therapy, acquired by a BP a few days ago, were to pass the current phase 3 trials, the price will be... beyond anything we can imagine !! It will remain the Rolls Royce of treatments (ok..) BUT.. for a very long time... ...AT THE PRICE of a Rolls Royce !! And it will take YEARS... before the price comes down... (after this new gene therapy FIRST...! reaches the commercialization phase...).
1 · Reply
Knowledgeworthmore
Knowledgeworthmore Oct. 25 at 6:45 PM
$OTLK you just talk crap they have 2 more drug that in phase-3 so you talk shit we invest for future, and those 2 drug in phase-3 as valuable as this one.
0 · Reply
Saltytimtation
Saltytimtation Oct. 25 at 6:13 PM
$OTLK the fda could have just simply requested them to withdraw if they didn’t see potential in approval. This can can only be kicked down the road for so long.
0 · Reply
IniG
IniG Oct. 25 at 10:10 AM
$OTLK Who in their right mind use off label unapproved Avastin when branded products like Eylea are available?
1 · Reply
updownsides
updownsides Oct. 25 at 5:19 AM
$OTLK Ixo-vec No more frequent injections. Who in their right mind would want to get many ongoing injections for the rest of their lives when a treatment like this can cure them for good? R I.P.
1 · Reply
Latest News on OTLK
Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 29, 2025, 8:45 AM EDT - 26 days ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA


Outlook Therapeutics Requests Type A Meeting with FDA

Sep 2, 2025, 8:35 AM EDT - 7 weeks ago

Outlook Therapeutics Requests Type A Meeting with FDA


FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 11:15 AM EDT - 2 months ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time


Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Jan 16, 2025, 12:09 PM EST - 10 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS


Top 3 Health Care Stocks That Could Blast Off This Month

Jan 6, 2025, 7:19 AM EST - 10 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT


Outlook Therapeutics® Streamlines Operations

Dec 13, 2024, 4:30 PM EST - 11 months ago

Outlook Therapeutics® Streamlines Operations


Outlook Therapeutics® Announces Executive Leadership Transition

Dec 3, 2024, 4:30 PM EST - 11 months ago

Outlook Therapeutics® Announces Executive Leadership Transition


Outlook Therapeutics: Worth A Good Strong Look After CRL

Jun 13, 2024, 5:22 PM EDT - 1 year ago

Outlook Therapeutics: Worth A Good Strong Look After CRL


SteelerJon
SteelerJon Oct. 25 at 11:45 PM
$OTLK Folks do yourself a favor block this guy. If not, quit reposting his posts so those of us who have blocked him don’t have to see your discussions….appreciate it…Thanks 😎🏦🏦
1 · Reply
RJtrade22
RJtrade22 Oct. 25 at 9:54 PM
$OTLK ok when’s the run up
1 · Reply
IniG
IniG Oct. 25 at 9:48 PM
$OTLK Thats no new information: the number of patients are growing and market is getting bigger. I think you believe in monopoly and not in competition. Lytenava has a very good advantage over all these that its a cost effective option and still works well.
0 · Reply
IniG
IniG Oct. 25 at 9:43 PM
$OTLK I don't know much about this therapy but I read this in your shared link. - Adverum had previously assessed the intravitreal injection in diabetic macular edema, an effort that was eventually discontinued after a patient ***went blind in the treated eye***. - The CVR entitles the holder to receive up to a total of $8.91 cash if ixo-vec is approved within ***seven years***
0 · Reply
updownsides
updownsides Oct. 25 at 9:25 PM
$OTLK You don't even know what your invested in. They have zero pipeline. Here is upcoming competition in a crowded space. Late/early-stage wet AMD drugs: ABBV-RGX-314 (Regenxbio/AbbVie, Ph3), ADVM-022 Ixo-vec (Adverum, Ph3), Tarcocimab KSI-301 (Kodiak, Ph3), 4D-150 (4DMT, Ph3), GB-102 (Graybug, Ph2b), OPT-302 (Opthea, Ph3 combo VEGF-C/D), EYP-1901 (EyePoint, Ph2), RGX-314 suprachoroidal (Regenxbio, Ph2), Faricimab Vabysmo (Roche, approved), Susvimo PDS (Roche, approved/relaunch). Some can eliminate injections altogether.
1 · Reply
NeurNet
NeurNet Oct. 25 at 7:14 PM
$OTLK @GenerallyGentle Your answer is very... relevant! Even if their (ticker ADVM : "ixo-vec") new gene therapy, acquired by a BP a few days ago, were to pass the current phase 3 trials, the price will be... beyond anything we can imagine !! It will remain the Rolls Royce of treatments (ok..) BUT.. for a very long time... ...AT THE PRICE of a Rolls Royce !! And it will take YEARS... before the price comes down... (after this new gene therapy FIRST...! reaches the commercialization phase...).
1 · Reply
Knowledgeworthmore
Knowledgeworthmore Oct. 25 at 6:45 PM
$OTLK you just talk crap they have 2 more drug that in phase-3 so you talk shit we invest for future, and those 2 drug in phase-3 as valuable as this one.
0 · Reply
Saltytimtation
Saltytimtation Oct. 25 at 6:13 PM
$OTLK the fda could have just simply requested them to withdraw if they didn’t see potential in approval. This can can only be kicked down the road for so long.
0 · Reply
IniG
IniG Oct. 25 at 10:10 AM
$OTLK Who in their right mind use off label unapproved Avastin when branded products like Eylea are available?
1 · Reply
updownsides
updownsides Oct. 25 at 5:19 AM
$OTLK Ixo-vec No more frequent injections. Who in their right mind would want to get many ongoing injections for the rest of their lives when a treatment like this can cure them for good? R I.P.
1 · Reply
updownsides
updownsides Oct. 25 at 3:42 AM
$OTLK Lilly buys cash-strapped Adverum for eye disease gene therapy https://share.google/ILIlJari2erLjkItq Getting crowded with more Big Pharma.
0 · Reply
superOTLK
superOTLK Oct. 25 at 2:33 AM
0 · Reply
superOTLK
superOTLK Oct. 25 at 2:24 AM
0 · Reply
superOTLK
superOTLK Oct. 25 at 2:23 AM
0 · Reply
superOTLK
superOTLK Oct. 25 at 2:22 AM
0 · Reply
The_Scientist
The_Scientist Oct. 25 at 1:29 AM
$OTLK Book of the Blind Eye — Chapter II: Defy the Bureaucrats 2:1 The FDA rattles, red tape their creed, We HODL through nonsense, ignore their greed, They shuffle in shadows, slow to heed— OTLK surges while their rules recede! 2:2 FUDsters howl, regulators scheme, We chant in vials, we ride the dream, No penny flips, no fear, no theme— Saint Optica crowns our biotech team! 2:3 Through crashes, dips, the timid fall, We mock their letters, we scorch the hall, Our ocular god laughs, triumphant call— OTLK forever, FDA to thrall! Amen
0 · Reply
GenerallyGentle
GenerallyGentle Oct. 24 at 10:49 PM
$OTLK Shorts are wising up. SI dropped dramatically the past few weeks. This was just updated today.
0 · Reply
Britbox
Britbox Oct. 24 at 8:40 PM
$OTLK good things coming. Load up
0 · Reply
Consti22
Consti22 Oct. 24 at 8:11 PM
$OTLK A good end to the week. 🤩 That makes the weekend so much nicer. 😊
1 · Reply
NeurNet
NeurNet Oct. 24 at 8:11 PM
$OTLK The week ends with.. 6.1%..overall ! Very good... steady...👍 The last 3 weeks : 9.2% 13.2% 9.3%. Have a great weekend everyone !!! 😉
0 · Reply
SilentJoker34
SilentJoker34 Oct. 24 at 8:08 PM
$OTLK What a close...💎🍻
0 · Reply
Britbox
Britbox Oct. 24 at 8:03 PM
$OTLK hopefully next week we get FDA minutes, which confirm a simple path forward (assuming the shut down doesn’t affect timeline) Maybe then, we’ll see that $1.50 again 
1 · Reply